Darlene Noci - 07 Jul 2022 Form 4 Insider Report for Nuvalent, Inc. (NUVL)

Role
SVP of Product Development & Regulatory Affairs Exhibit List: Exhibit 24 - Limited Power of Attorney
Signature
/s/ Deborah A. Miller, attorney-in-fact
Issuer symbol
NUVL
Transactions as of
07 Jul 2022
Net transactions value
-$277,704
Form type
4
Filing time
08 Jul 2022, 16:17:29 UTC
Previous filing
16 Feb 2022
Next filing
19 Jul 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NUVL Class A Common Stock Options Exercise $18,144 +16,800 $1.08* 16,800 07 Jul 2022 Direct F1
transaction NUVL Class A Common Stock Sale $295,848 -16,800 -100% $17.61 0 07 Jul 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NUVL Stock Option (Right to Buy) Options Exercise $0 -16,800 -10% $0.000000 149,589 07 Jul 2022 Class A Common Stock 16,800 $1.08 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 22, 2021.
F2 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.05 to $18.06, inclusive. The reporting person undertakes to provide to the staff of the Securities and Exchange Commission, Nuvalent, Inc. or any security holder of Nuvalent, Inc., upon request, full information regarding the number of shares sold at each separate price.
F3 The shares underlying this option vest as follows: 25% of the shares vested on January 11, 2022, and the remainder vest over the next three years thereafter in equal monthly installments, subject to continued service to Nuvalent, Inc. through the applicable vesting date.

Remarks:

SVP of Product Development & Regulatory Affairs Exhibit List: Exhibit 24 - Limited Power of Attorney